נורווסק 5 מג טבליות ישראל - עברית - Ministry of Health

נורווסק 5 מג טבליות

pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

סיאנה ישראל - עברית - Ministry of Health

סיאנה

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

סוטנט 12.5 מג ישראל - עברית - Ministry of Health

סוטנט 12.5 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 25 מג ישראל - עברית - Ministry of Health

סוטנט 25 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 50 מג ישראל - עברית - Ministry of Health

סוטנט 50 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 250 מג ישראל - עברית - Ministry of Health

קסאלקורי 250 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 250 מג ישראל - עברית - Ministry of Health

קסאלקורי 250 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

אינלייטה 1 מג ישראל - עברית - Ministry of Health

אינלייטה 1 מג

pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 1 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.